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 The present trial investigated the effect of PCV2 vaccination on viremia, virus 
shedding and viral load in maternal tissues and foetuses of conventional gilts 
inseminated with PCV2b-spiked semen. Twelve gilts were randomly divided into 
two groups of six animals each (vaccinated infected, VI; non-vaccinated infected, 
NVI). Estrus synchronization was followed by artificial insemination (AI) with a 
single PCV2 negative semen dose supplemented with 0.2 mL of a PCV2b 
suspension containing 104.4 TCID50/50 µL (total viral dose: 105 TCID50). Vaginal, 
nasal and faecal swabs, and blood samples were collected weekly from two days 
before artificial insemination  till the end of the experimental period (55 days post 
AI; DPAI) and tested by real-time PCR (qPCR) for PCV2; sera were tested for anti-
PCV2 antibodies. During necropsy foetal and maternal tissues were collected for 
qPCR and histopathology. In each of the VI and NVI groups three out of the six 
gilts were pregnant at 29 DPAI. The VI group showed a significantly lower 
proportion of PCR-positive swabs: 24.6% VI vs 71.3% NVI. PCV2 clearance was 
demonstrated by qPCR in lymphoid tissue during the trial in the VI group. Only one 
foetus was PCV2-positive (in the NVI group) and three amniotic fluids of the NVI 
group. PCV2 was found in a significantly lower proportion of the placenta of 
foetuses in the VI group (39%) than the NVI group (77%). The PCV2 vaccine 
seems to play an active role in reducing virus shedding, tissue viral load and foeto-
placental infection. 
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INTRODUCTION 
 
Porcine circovirus type 2 (PCV2) infections is a 
globally important issue in intensive swine farms. PCV2 
rarely causes clinical diseases, but when it does, 
pleomorphic faceted syndromes manifest, often in 
combination with opportunistic pathogens. The clinical 
manifestations are known as porcine circovirus diseases 
(PCVD) or porcine circovirus-associated diseases 
(PCVAD) in the EU or USA, respectively (Opriessnig et 
al., 2007; Segalés, 2012).  
PCV2 has been linked to stillbirth, mummification, 
embryonic death, infertility and abortion (SMEDIA) 
syndrome, and in recent years it has been established that 
reproductive disorders characterized by acute events 
affect gilts or low-parity sows and PCV2-free herds. 
Manifestations affecting reproduction can be divided into 
clinical and subclinical events. Clinical events include 
evident SMEDIA-like disorders with delivery of piglets 
showing macroscopic and microscopic lesions caused by 
PCV2, while subclinical events include vertical 
transmission with delivery of PCV2-infected piglets but 
without lesions or indication of reproductive failure 
(Madson and Opriessnig, 2011). Vertical transmission of 
PCV2 has been successfully demonstrated and reproduced 
in a number of experimental and field trials (Madson et 
al., 2009a; Hansen et al., 2010; Nathues et al., 2011). 
Horizontal transmission between gestating sows is equally 
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important in increasing the risk of viremia that causes 
vertical transmission to foetuses (Gerber et al., 2012).  
An important tool to control PCV2 infection is 
vaccination of sows to avoid clinical manifestations, 
reduce the frequency and magnitude of viral shedding, 
and accordingly cut economic losses. Field evidence and 
specific field trials have demonstrated that vaccination 
against PCV2 improves the sow’s reproductive 
parameters by increasing the mean number of live born 
and weaned piglets per sow per year (Pejsak et al., 2012; 
Maurin-Bernaud et al., 2012).  
As gilts are at the highest risk of PCV2-induced 
reproductive disorders (Madson and Opriessnig, 2011), 
this paper presents the results of an experimental 
challenge in controlled conditions designed to evaluate the 
influence of PCV2 vaccination on the dynamics of PCV2 
infection in the dam and its vertical transmission to 
foetuses in conventional gilts inseminated with PCV2b-
spiked semen. We evaluated the ability of the vaccination 
to reduce and limit not only maternal infection and related 
events (viremia and shedding), but also vertical 
transmission to foetuses, focusing on the first half of 
pregnancy (days 0-55). 
 
MATERIALS AND METHODS 
 
Animals: Twelve Large White conventional female 
piglets were randomly selected from animals on a 
breeding farm that had a policy of vaccination against 
porcine parvovirus (PPV), Aujeszky disease virus (ADV) 
and erysipelas. They were divided into two groups 
(vaccinated infected, VI and non-vaccinated infected, 
NVI) of six gilts each (VI-1-6; NVI-1-6) and group VI 
gilts were vaccinated at the farm with Circovac® 
(Merial, Lyon, France, batch L357004) according to the 
datasheet. At about 160 days of life, the gilts (mean live 
body weight ± SD: 98.5 ± 9.4 Kg) were housed in 
individual pens of about 6 m2 in two separate rooms with 
restricted access (University of Bologna facilities). On a 
daily basis, the rectal temperature was measured and a 
physical examination performed. The experimental 
procedures were approved by the Animal 
Experimentation Ethical and Scientific Committee - 
Alma Mater Studiorum, University of Bologna and 
subsequently approved by the Italian Ministry of Health. 
The study was carried out in accordance with European 
legislation regarding the protection of animals used for 
experimental and other scientific purposes (Council 
Directive 86/609/EEC). 
 
Experimental design: The days of the trial were 
indicated by the abbreviation DPAI (days post artificial 
insemination); 0 DPAI is the time of insemination with 
semen supplemented with PCV2b. The whole in vivo trial 
took 60 days (from -4 to 55 DPAI). 
On -4 DPAI a pharmacological treatment started to 
induce puberty, oestrus and superovulation: 1500 UI/gilt 
of Folligon™ (Intervet, Boxmeer, The Netherlands) were 
intramuscularly administered and then, at -2 DPAI, 750 
UI/gilt of Corulon™ (Intervet) were given according to 
Sarli et al. (2012). Insemination with PCV2b-spiked 
semen was performed on 0 DPAI, approximately 40 hours 
after the Corulon™ administration. All animals were 
inseminated once with 100 mL PCV2 negative semen 
supplemented with 0.2 mL of a PCV2b suspension 
containing 104.4 TCID50/50 µL (total viral dose: 105 
TCID50). The PCV2b strain was the same used by Sarli et 
al. (2012). Preliminarily, the semen had been tested by 
PCR to exclude the presence of PCV2 genome (Sarli et 
al., 2012). 
At 29 DPAI, ultrasonographic diagnosis of pregnancy 
was performed. Gilts that aborted and non- pregnant 
animals underwent euthanasia after abortion or 
ultrasonography to assess the presence of possible lesions, 
while the pregnant animals were pharmacologically 
euthanized between 49 and 55 DPAI, adopting the 
following protocol: a) 8 mL of Stresnil® (Janssen Animal 
Health, Beerse, Belgium) IM.; b) 25 mL of Ketavet100® 
(Intervet Productions S.r.l., Milan, Italy) IM after 20 min; 
c) 10 mL of 50 mg/mL Pentothal Sodium® (Intervet 
Productions S.r.l., Milan, Italy) IV after 20 min; d) 10 mL 
of Tanax® (Intervet Italia, Latina, Italy) IV. 
 
In vivo sampling: From -2 DPAI to the day of 
euthanasia, weekly blood samples, nasal, faecal and 
vaginal swabs were collected to detect PCV2 viral 
shedding by means of real-time PCR (qPCR). On 14 
DPAI blood sampling was not performed to avoid stress 
during the maternal recognition of pregnancy. Serum 
antibody titres against PCV2, porcine reproductive and 
respiratory syndrome virus (PRRSV), ADV and PPV 
were determined by testing serial dilutions of each serum 
sample through competitive ELISA assay (Sarli et al., 
2012). The anti-PCV2 antibody titration was performed 
weekly; antibodies against ADV, PPV and PRRSV were 
titrated on the first (-2 DPAI) and last (intra-mortem) 
sampled serum. Serum progesterone (ng/mL P4) was 
detected by validated radioimmunoassay with sensitivity 
2.2 pg/tube; intra- assay CV 5.7%; inter-assay CV 10.5%; 
Sarli et al., 2012).  
 
Post mortem sampling: Gilts underwent full post-
mortem examination. Samples of lymphoid organs 
(lymphoid tissue set: tonsils, inguinal and uterine lymph 
nodes), reproductive tract [reproductive tissue set: ovary 
(ovarian functional structures - follicles, corpora lutea, 
corpora albicantia - were counted), oviduct, uterus, cervix, 
vagina, feto-placental unit] and other organs [small 
intestine (duodenum, jejunum, ileum), liver, kidney, heart 
and lung] were collected. Each foetus was weighted and 
crown-rump length measured to estimate the gestational 
age according to Kirkwood et al. (2012). Sampled tissue 
sets from each feto-placental unit comprised: amniotic 
fluid, allantochorion, spleen, heart and liver (these organs 
were pooled); to avoid cross-contamination between 
foetuses sterile surgical tools were used.  
 
Real-time PCR and sequencing: Viral DNA was 
extracted (from swabs, sera, lymphoid and reproductive 
tissue sets) and quantified via qPCR for PCV2 (Sarli et 
al., 2012). To evaluate the identity between the PCV2b 
strain used for infection and the strain detected in tissues, 
DNA sequencing was carried out on 10 randomly selected 
qPCR-positive samples of lymphoid and reproductive 
organs. PCV2 PCR was run in accordance with Ouardani 
et al. (1999). DNA amplification and quality were then 
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checked on a 1% agarose gel in 1x TAE buffer. The 
amplicons were purified with a column-based system 
(Macherey-Nagel), testing both amplified samples and 
excised DNA fragments from agarose gel after 
electrophoresis. The samples were then sent to the 
Eurofins-MWG-Operon’s sequencing service (Ebersberg, 
Germany). All sequences passed the quality control 
standards. The amplified ORF2 fragment was sequenced 
and compared both with Genebank reference sequences 
(PCV2a AF465211; PCV2b HM038022.1) and the 
PCV2b strain used for infection (PCV2b 6503, IZSLER, 
Brescia, Italy). The Basic Local Alignment Search Tool 
(BLAST) was used to identify sequence similarity, 
choosing a cut-off of 98% similarity among tested 
genomes. 
 
Histopathology and immunohistochemistry: All 
sampled tissues were subjected to routine histological 
examination (H&E). Immunohistochemistry was run only 
on qPCR-positive tissues of lymphoid and reproductive 
tissue sets, with >108 PCV2 genomic copies/mL using a 
monoclonal antibody (PCV2 Mab F217), as previously 
described (Sarli et al., 2009). To increase the sensitivity, a 
streptavidin-biotin-peroxidase polymeric complex 
(SuperPicture kit peroxidase, ZymedR Lab, San 
Francisco, USA) was used. 
 
Statistical analysis: The Kolmogorov–Smirnov test for 
goodness of adaptation was used to verify distribution 
normality. On the basis of the results of this test, Mann-
Whitney (M-W) U test was used to compare quantitative 
data (PCV2 genomic load of tissues, swabs and blood 
samples, anti PCV2 antibody titre in animals of the two 
groups). Wilcoxon signed-ranks test for repeated 
measures was used to analyze the antibodies dynamics for 
ADV, PPV and PRRSV. The proportion of PCV2-positive 
samples (blood, reproductive and lymphoid tissue sets, 
swabs) was analyzed with Chi-square test. Data were 
analyzed with the SPSS 19.0 (SPSS Inc., Chicago, USA). 
 
RESULTS  
 
In vivo and post mortem: On 0 DPAI all gilts showed 
immobility reflex and oestrus signs. After artificial 
insemination no oestrus signs were detected and a rise in 
serum P4 was evident (-2 DPAI: P4=0.2±0.28 ng/mL; 7 
DPAI: P4=21.91±7.06 ng/mL). 
Gilts NVI-5, VI-3 and VI-4 aborted at 20, 22 and 24 
DPAI, respectively. At 29 DPAI, ultrasound examination 
proved pregnancy in VI-1, VI-5, VI-6, NVI-3, NVI-4 and 
NVI-6 gilts. The serum P4 decreased to low values on 21 
DPAI in non-pregnant gilts (1.35±1.75 ng/mL), while 
pregnant animals maintained high levels of serum P4 
(18.60±5.28 ng/mL at 21 DPAI). Non-pregnant animals 
were sacrificed on 34 (VI-2), 23 (VI-3), 25 (VI-4), 33 
(NVI-1), 33 (NVI-2) and 22 (NVI-5) days post artificial 
insemination (mean 29 DPAI). Pregnant gilts were 
euthanized on 54 (VI-1), 49 (VI-5), 50 (VI-6), 51 (NVI-
3), 49 (NVI-4), 55 (NVI-6) days post artificial 
insemination (mean 53 DPAI). 
Three, 15, 9, 10, 16 and 14 foetuses were collected 
from gilts VI-1, VI-5, VI-6, NVI-3, NVI-4 and NVI-6, 
respectively.  The size of all foetuses was compatible with  
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Fig. 1: Mean titres (log6) of serum antibodies to PCV2 in gilts per group 
at different days post AI.   
 
 
 
Fig. 2: Proportion of PCV2 real-time PCR-positive lymphoid tissue at 
the two sampling times. 
 
gestational age and no gross lesion was observed. Ovarian 
functional structures were consistent with the number of 
foetuses (mean±SD corpora lutea: 15±6.6 and 2.6±4.4 in 
pregnant and non-pregnant gilts, respectively; mean 
corpora albicantia of non-pregnant animals: 6.4±3.5). The 
uterus of non-pregnant gilts showed a prepubertal 
appearance, with a mild ovarian response to 
pharmacological treatment, and ovarian functional 
structures were manifestation of a second cycle after the 
first, induced estrus, not followed by a successful 
pregnancy. 
 
Serology: No statistically significant difference (P>0.05) 
in the mean antibody titre against PCV2 was detected 
between the two groups at -2, 7, 21 and 28 DPAI. At 35 
DPAI the mean antibody titre against PCV2 of group NVI 
pigs was significantly higher (P<0.05) than that of VI 
pigs, followed by a slight increase in mean antibody titre 
on 42 DPAI in group VI (Fig. 1). 
All the animals had serum antibodies against PRRSV 
on -2 DPAI, but the antibody titres significantly decreased 
on intra-mortem sampling (P<0.05). Anti-ADV (anti-gB) 
and anti-PPV antibody titre showed a decreasing trend 
during the trial; no anti-ADV-gE antibodies were 
detected. Results indicated that no infection with PRRSV, 
ADV and PPV occurred during the trial. 
 
PCV2 in blood, swabs and tissues: PCV2 DNA was 
detected in four gilt blood samples (NVI-2, NVI-3, NVI-
5, NVI-6) at the beginning of the experiment (-2 DPAI).
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Table 1: PCV2 assessment by real-time PCR in faecal, vaginal and nasal swabs, blood, lymphoid tissue set and reproductive tissues set 
Sample Group Positive (%) Negative (%) Total P 
Faecal swab VI 12 (28.6) 30 (71.4) 42 < 0.001 NVI 38 (88.4) 5 (11.6) 43  
total  50 (58.8) 35 (41.2) 85  
Vaginal swab VI 6 (14.3) 36 (85.7) 42 < 0.001 NVI 25 (58.1) 18 (41.9) 43  
total  31 (36.5) 54 (63.5) 85  
Nasal swab VI 13 (31.0) 29 (69.0) 42 <0,001 NVI 29 (67.4) 14 (32.6) 43  
total  42 (49.4) 43 (50.6) 85  
Blood VI 2 (5.7) 33 (94.3) 35 < 0.001 NVI 21 (56.8) 16 (43.2) 37  
total  23 (31.9) 49 (68.1) 72  
Lymphoid tissues  VI 15 (41.7) 21 (58.3) 36 < 0.001 NVI 36 (100) 0 (0) 36  
total  51 (70.8) 21 (29.2) 72  
Reproductive tissues* VI 62 (39.5) 95 (60.5) 157 < 0.001 NVI 121 (58.2) 87 (41.8) 208  
total  183 (50.1) 182 (49.9) 365  
Foeto-placental units ** VI 11 (13.1) 73 (86.9) 84 < 0.01 
 NVI 35 (28.7) 87 (71.3) 122  
total  46 (22.3) 160 (77.7) 206  
*Included ovaries, oviduct, uterus, cervix, vagina, foetuses, placenta and amnios; **Data obtained considering the total of foetuses+placenta+amnios 
samples (feto-placental units). 
 
Table 2: Comparison between VI and NVI groups of genomic load 
(expressed as Log10 genomic copies/mL) for swabs, blood and tissue 
samples (reproductive tissue set and lymphoid tissue set).  
Sample Genomic load (mean Log10 PCV2 genomic copies/mL) 
P 
 Group VI  Group NVI  
Faecal swab 0.00 4.32 < 0.001 
Vaginal swab 0.00 3.50 < 0.001  
Nasal swab 0.00 3.86 < 0.001 
Blood 0.00 2.98 < 0.001  
Lymphoid tissues 3.96 10.12 < 0.001  
Ovary 4.04 6.57 0.014 
Oviduct 5.26 6.93 0.038 
Uterus 4.59 5.18 0.012 
Cervix 3.76 6.46 0.11 
Vagina 4.50 6.80 0.030 
Foeto-placental units* 0.71 1.31 0.020 
Tonsil 4.53 10.45 < 0.001 
Uterine lymph node 3.70 9.22 < 0.001 
Inguinal lymph node 3.12 9.89 < 0.001 
Total (all samples) 2.51 4.24 < 0.001 
*Data obtained considering the total of foetuses+placenta+amnios 
samples (feto-placental units). 
 
 
 
Fig 3: NVI-1, left tonsil. PCV2 immunohistochemistry. The lymphoid 
follicle shows a reticular labelling pattern (cytoplasmic localization in 
follicular dendritic cell of PCV2 antigen). DAB chromogen, 
haematoxylin counterstain. Obj 40x, Scale bar=50 µM. 
 
Animals in the NVI group displayed a significantly higher 
proportion (P<0.001) of PCV2 viremic events (56.8%) 
throughout the trial, whereas the VI group animals were 
rarely viremic (5.7%; Table 1). 
The proportion of total (nasal+ vaginal + faecal) 
PCV2-positive swabs was significantly lower (P<0.001) 
in the VI group (24.6%) than in the NVI group (71.3%; 
Table 1). Samples collected from VI gilts had a 
significantly lower genomic load than those collected 
from NVI animals, and was non-significant only in the 
comparison of the cervix data (Table 2). 
In both groups (NVI and VI), data were available for 
two sampling times: 29 DPAI, i.e. the mean sampling 
time of the aborted/non-pregnant animals (3 NVI and 3 
VI) and 53 DPAI, i.e. the mean sampling time of the 
pregnant gilts (3 NVI and 3 VI). Comparing the 
proportion of qPCR PCV2-positive lymphoid tissues in 
each group at the two sampling times (29 DPAI vs 53 
DPAI), a decreasing trend was identified in the VI group 
(Fig. 2). The same trend was apparent even at analysing 
the sum of PCV2 genomic load of tissues belonging to two 
tissue sets compared between the two groups (Table 2). 
Considering only pregnant animals, the comparison 
between the two groups showed a significantly higher 
PCV2 genomic load in foeto-placental units (foetal + 
amniotic + placental samples) of the NVI group (P<0.01). 
Only one foetal PCV2 positivity was detected in gilt NVI-
3. PCV2 was found in the placenta of 11 out of 28 (39%, 
VI) and 31 out of 40 (77%, NVI) foetuses (P<0.01; Table 
1).  
The BLAST identified regions of local similarity 
between the PCV2b strain used for experimental infection 
and detected strain sequences higher than 98% only in one 
case out of 10 (99% homology) in a uterine segment 
adjacent to a foetus  of gilt VI-5. The other nine sequences 
proved to be PCV2a strains. Moreover, the strain used for 
infection shared 99% similarity with Genebank sequence 
PCV2b HM038022.1. 
 
Histopathology and immunohistochemistry: Histo-
pathological hallmarks of PCVDs were absent. Only in six 
lymphoid tissues (tonsil and lymph node) of gilts NVI-1 
and NVI-2 cytoplasmic immunolabeling to PCV2 was 
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detectable in scattered histiocytes and follicular dendritic 
cells (Fig. 3). Other recorded lesions were “background” 
lesions of conventional pigs: mild enzootic pneumonia or 
fibrosing pleuritis (n=5), mild interstitial hepatitis (n=2), 
mild erosions/ulcers on gastric pars oesophagea (n=2). No 
differences between groups were present. Other organs 
were grossly unremarkable and histology did not reveal 
any lesions. 
 
DISCUSSION 
 
This study was conducted in conventional gilts 
simulating the effect of PCV2 vaccination under field 
conditions. Already before infection (-2 DPAI), some of 
the animals used showed PCV2 viremia and all were 
PCV2 antibody-positive. The experimental infection with 
PCV2b-spiked semen was effective in inducing an 
increase in anti-PCV2 antibodies in both groups, similar 
to data reported with non-conventional sows (Madson et 
al., 2009b). Recent field experiments, experimental trials 
and investigations supported the hypothesis that swine 
herds are infected by a swarm of PCV2 genotypes, which 
can cause prolonged viremia, reinfection, and coinfection, 
predisposing to recombination (Khaiseb et al., 2011; 
Gerber et al., 2012). As PCV2 infections by different 
strains or genotypes may overlap in field conditions, there 
were also coinfections of different PCV2 strains in our 
experimental trial because PCV2a, prevalent and due to a 
spontaneous infection, were detected in addition to the 
strain used for experimental infection. Sequencing results 
confirmed the possibility of PCV2a/b coinfection (Zhai et 
al., 2011) at least in some of the tested animals. Detection 
of the PCV2b genome used for the infection in the tested 
samples demonstrated the ability to induce a coinfection 
in subjects already positive for PCV2a. 
Vaccination of gilts and sows aims also to reduce the 
spread of PCV2 in the breeding sector (Madson and 
Opriessnig, 2011). Vaccination efficacy should be viewed 
pragmatically as the capacity to hold and restrain the 
negative outcomes, shedding and viremia, that maximize 
the risk of horizontal and vertical transmission, mainly in 
the breeding sector. Most studies on the effect of PCV2 
vaccination on sow performance sought to demonstrate a 
positive effect on reproductive parameters (reduced 
preweaning pig mortality, improved farrowing rates) 
(Joisel et al., 2008; Schøning et al., 2008; Maurin-
Bernaud et al., 2012) in field conditions, and only two 
addressed the experimental demonstration of in utero 
PCV2 replication (Madson et al., 2009b; Madson et al., 
2009c). The PCV2 present in blood and swab sets (fecal, 
vaginal and nasal) from the present trial was significantly 
lower in vaccinated animals, confirming the role of the 
vaccine in reducing shedding contributing to decreased 
horizontal transmission.  
The fact that four out of the 12 gilts were viremic 
before infection (-2 DPAI) is consistent with the 
widespread infection of conventional pigs with PCV2. 
Shedding mirrors viremia (Patterson et al., 2011; Rose et 
al., 2012) that was lower in vaccinated animals, a 
condition that reduced the probability of shedding and 
minimized vertical transmission. No vaccinated gilt was 
viremic on -2 DPAI, suggesting vaccination has a 
protective effect. The only PCV2 qPCR-positive foetus 
belonged to sow NVI-3, while in the VI group no foetal 
positivity was recorded. Sow NVI-3 displayed an 
intermediate antibody titre at -2 DPAI and was viremic 
throughout the trial. This finding supports the hypothesis 
that prolonged viremia is a source of foetal infection 
(Madson and Opriessnig, 2011) and the risk can be 
reduced by the vaccine’s effect on viremia. Foetal 
infection arises by transplacental cross of PCV2. From 
this point of view placental infection is a prodromic event 
leading to foetal infection and the lower percentage of 
placentas positive to PCV2 in VI gilts should be 
considered a protective effect of the vaccine to prevent the 
foetal infection. A similar vaccine effect was shown in 
other studies in which conclude that PCV2 infection of 
naïve pregnant sows may not result in reproductive failure 
but can be associated with foetal infection alone (Madson 
et al., 2009b; Madson et al., 2009c). 
Lymphoid compartments are privileged sites for 
PCV2 amplification. In this tissue set a decrease of 
genomic viral load was seen during the trial by comparing 
the percentages of positive samples collected from non-
pregnant animals at 29 DPAI with those collected from 
pregnant animals at 53 DPAI. This viral clearance was 
identified in vaccinated individuals only, while the NVI 
group had higher concentrations at both 29 and 53 DPAI 
sampling times. Furthermore, PCV2 genomic viral load, 
regardless of the two moments, was higher in NVI. This 
could be interpreted as an effective PCV2 clearance due to 
vaccination in VI animals. One of the consequences of 
this viral clearance is the lower frequency of viremic 
events and PCV2 shedding in vaccinated gilts. 
 
Conclusions: PCV2 vaccine seems to play an active role 
in reducing virus shedding and tissue viral load in sows. 
The experimental data reported here support the 
hypothesis that vaccination of gilts before artificial 
insemination with PCV2-spiked semen had a protective 
effect against both horizontal and vertical transmission. 
PCV2 vaccination in the pig breeding sector benefits in 
utero foetuses because of a reduction of PCV2 viremia in 
their dam. 
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